Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel

Rhea-AI Summary

Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company specializing in oral integrin therapies, announced that COO and CFO Marc Schegerin, M.D. will join a panel on "Novel Approaches Tackling Autoimmune Conditions" at the BMO Biopharma Spotlight Series on April 6, 2022. The event will focus on innovative strategies for addressing autoimmune diseases. Morphic is collaborating with prominent companies like AbbVie and Janssen to advance their pipeline using the proprietary MInT technology platform, aimed at treating chronic diseases including autoimmune disorders, cardiovascular issues, and cancer.

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic COO and CFO Marc Schegerin, M.D. will participate in panel discussion titled “Novel Approaches Tackling Autoimmune Conditions” at the BMO Biopharma Spotlight Series on Inflammation & Immunology on Wednesday April 6^th 2022.

About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718

 

FAQ

What is the date of the BMO Biopharma Spotlight Series event featuring Morphic's Marc Schegerin?

The BMO Biopharma Spotlight Series event will take place on April 6, 2022.

Who from Morphic Therapeutic will participate in the panel discussion?

Marc Schegerin, M.D., COO and CFO of Morphic Therapeutic, will participate in the panel discussion.

What are the main focuses of Morphic Therapeutic's research?

Morphic Therapeutic focuses on oral integrin therapies for chronic diseases, including autoimmune, cardiovascular, and metabolic diseases.

Which major companies is Morphic collaborating with?

Morphic is collaborating with AbbVie, Janssen, and Schrödinger on its research and development.

What technology platform does Morphic Therapeutic use?

Morphic Therapeutic utilizes its proprietary MInT technology platform to advance its drug discovery activities.